세계의 암 프로파일링 시장 보고서(2025년)

Cancer profiling refers to a diagnostic procedure aimed at analyzing the genetic information within tumor cells in the body. This process provides crucial insights into specific molecular or genetic alterations present in a tumor, such as gene mutations or other changes occurring in tumor DNA.

Key technologies involved in cancer profiling encompass immunoassays, PCR (polymerase chain reaction), NGS (next-generation sequencing), microarrays, and in-situ hybridization. Immunoassays represent laboratory tests designed to measure the concentration of specific proteins or other biomolecules found in blood or urine samples. Genomic biomarkers and protein biomarkers are utilized for profiling various cancers, including breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer, and others. These profiling methods find applications in research, clinical diagnostics, screening, prognostics, and other healthcare-related purposes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cancer profiling market research report is one of a series of new reports from The Business Research Company that provides cancer profiling market statistics, including cancer profiling industry global market size, regional shares, competitors with a cancer profiling market share, detailed cancer profiling market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer profiling industry. This cancer profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer profiling market size has grown rapidly in recent years. It will grow from $13.48 billion in 2024 to $15 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing cancer incidence rates, rise in precision medicine approaches, clinical adoption of biomarkers, drug development and targeted therapies, awareness, and patient advocacy.

The cancer profiling market size is expected to see rapid growth in the next few years. It will grow to $22.97 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to integration of artificial intelligence, global collaborations in research, expansion of liquid biopsy applications, regulatory support for precision medicine, increasing emphasis on early detection. Major trends in the forecast period include liquid biopsy dominance, comprehensive genomic profiling, rise of immunoprofiling, collaborative data sharing network, single-cell sequencing.

The forecast of 11.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. molecular oncology by inflating prices of next-generation sequencing panels and bioinformatics analysis platforms developed in Israel and Singapore, resulting in delayed treatment decisions and higher genomic testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the incidence of cancer is poised to drive the growth of the cancer profiling market in the coming years. Cancer incidence, representing the number of new cancer cases within a specific population during a defined period, is on the ascent due to factors such as urbanization, an expanding aging demographic, evolving lifestyles, and various environmental and genetic influences. The surge in cancer cases underscores the importance of cancer profiling, a process that identifies specific molecular or genetic alterations in tumors, aiding in the comprehensive understanding and treatment of cancer. In 2022, the American Cancer Society projected an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the United States, highlighting the pressing need for advanced profiling techniques to address the increasing cancer burden.

The growing funding for cancer research is expected to drive the growth of the cancer profiling market in the future. Funding for cancer research refers to financial backing from various sources to support scientific investigations aimed at expanding knowledge, developing treatments, and discovering cures for different types of cancer. Cancer profiling enables targeted and personalized treatment approaches based on the molecular characteristics of cancer. For example, in 2023, the American Society for Radiation Oncology (ASTRO), a US-based organization focused on advancing radiation oncology, reported that the National Institutes of Health (NIH) received $51 billion in funding, with $9.988 billion directed to the National Cancer Institute (NCI), reflecting a $2.7 billion increase from the 2023 fiscal year. As a result, the rise in funding for cancer research is fueling the growth of the cancer profiling market.

Leading companies in the cancer profiling market are prioritizing innovation, such as expanding test coverage. These tests evaluate 517 cancer-related genes across nearly 30 solid tumor types. Broad coverage involves the comprehensive analysis of a wide range of genetic mutations, biomarkers, or molecular targets. For example, in March 2022, Illumina, Inc., a US-based biotechnology firm, introduced the TruSight Oncology Comprehensive (TSO) test, representing a significant breakthrough in cancer diagnostics. This new in vitro diagnostic test, launched in Europe, profiles cancer mutations to guide patients toward targeted therapies. It examines 517 genes from both DNA and RNA across nearly 30 solid tumor types, providing faster results within four to five days. CE-marked for European quality standards, the test reduces the need for multiple gene assays from different tissue samples.

Key players in the cancer profiling market are strategically focusing on the development of innovative in-vitro diagnostic test kits to optimize the treatment of advanced non-small cell lung cancer (NSCLC). In-vitro diagnostic test kits are specialized medical devices designed for the analysis of specimens, such as blood or tissue, outside the living organism (in vitro). One notable example is Qiagen, a leading Germany-based provider of sample and assay technologies. In May 2022, Qiagen launched the Thera screen EGFR Plus RGQ PCR Kit, an in-vitro diagnostic test specifically crafted for the sensitive analysis of EGFR mutations in non-small cell lung cancer (NSCLC) treatment. This real-time quantitative polymerase chain reaction (qPCR) test enhances detection limits, ensures faster turnaround times, and streamlines the process with automated sample extraction and results analysis. Notably, the kit now encompasses the detection of the C797S mutation, a crucial biomarker indicating resistance to third-generation EGFR tyrosine kinase inhibitors. This strategic development underscores the commitment of major industry players to advancing precision diagnostics in cancer treatment.

In January 2023, Agilent Technologies, a US-based biotechnology research company, acquired Avida Biomed Inc. for an undisclosed sum. The acquisition is intended to strengthen Agilent's expertise in molecular biology, particularly in advancing innovative tools and technologies for synthetic biology applications. Avida Biomed Inc. is also a US-based biotechnology research company.

Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer profiling market consists of revenues earned by entities by providing services such as surgery, chemotherapy, radiotherapy, hormonal therapy, and immunotherapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. Cancer profiling also includes sales of diagnostic tests and spectrometers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Profiling Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer profiling market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Technology: Immunoassays; PCR (Polymerized Chain Reaction); NGS (Next-Generation Sequencing); Microarrays; In-Situ Hybridization
• 2) By Biomarker Type: Genomic Biomarkers; Protein Biomarkers
• 3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma Cancer; Other Cancers
• 4) By Application: Research Applications; Clinical Applications; Screening; Diagnostics; Prognostics; Other Applications
• Subsegments:
• 1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Luminex xMAP Technology; Radioimmunoassays
• 2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR); Digital PCR (dPCR); Reverse Transcription PCR (RT-PCR)
• 3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Sequencing; RNA Sequencing (RNA-Seq)
• 4) By Microarrays: DNA Microarrays; RNA Microarrays; SNP Arrays
• 5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH); Chromogenic In-Situ Hybridization (CISH)
• Companies Mentioned: Illumina Inc.; Qiagen NV; NeoGenomics Inc.; Sysmex Corporation; HTG Molecular Diagnostics Inc.; Caris Life Sciences; NanoString Technologies Inc.; Guardant Health Inc.; Foundation Medicine Inc.; Roche Diagnostics Corporation; F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Genscript Biotech Corporation; Tempus Labs Inc.; Hologic Inc.; Predictive Oncology Inc.; Abbott Laboratories; Agilent Technologies Inc.; PerkinElmer Inc.; Siemens Healthineers; Genomic Health Inc.; Natera Inc.; ArcherDX Inc.; Personal Genome Diagnostics Inc.; Enzo Biochem Inc.; Cancer Genetics Inc.; OncoDNA SA; Ribomed Biotechnologies Inc.; Biocartis Group NV; N-of-One Inc.; Cynvenio Biosystems Inc.; Inivata Ltd.; Burning Rock Biotech Limited; PathAI Inc.; GENEWIZ Inc.; Genoptix Inc.; Oncomine Dx Target Test; OmniSeq Comprehensive; Resolution Bioscience; OncoCyte Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Profiling Market Characteristics

3. Cancer Profiling Market Trends And Strategies

4. Cancer Profiling Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cancer Profiling Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer Profiling PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer Profiling Market Growth Rate Analysis
• 5.4. Global Cancer Profiling Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer Profiling Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer Profiling Total Addressable Market (TAM)

6. Cancer Profiling Market Segmentation

• 6.1. Global Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoassays
• PCR (Polymerized Chain Reaction)
• NGS (Next-Generation Sequencing)
• Microarrays
• In-Situ Hybridization
• 6.2. Global Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genomic Biomarkers
• Protein Biomarkers
• 6.3. Global Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancers
• 6.4. Global Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Research Applications
• Clinical Applications
• Screening
• Diagnostics
• Prognostics
• Other Applications
• 6.5. Global Cancer Profiling Market, Sub-Segmentation Of Immunoassays, By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Western Blotting
• Luminex xMAP Technology
• Radioimmunoassays
• 6.6. Global Cancer Profiling Market, Sub-Segmentation Of PCR (Polymerase Chain Reaction), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Quantitative PCR (qPCR)
• Digital PCR (dPCR)
• Reverse Transcription PCR (RT-PCR)
• 6.7. Global Cancer Profiling Market, Sub-Segmentation Of NGS (Next-Generation Sequencing), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)
• Targeted Sequencing
• RNA Sequencing (RNA-Seq)
• 6.8. Global Cancer Profiling Market, Sub-Segmentation Of Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA Microarrays
• RNA Microarrays
• SNP Arrays
• 6.9. Global Cancer Profiling Market, Sub-Segmentation Of In-Situ Hybridization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluorescence In-Situ Hybridization (FISH)
• Chromogenic In-Situ Hybridization (CISH)

7. Cancer Profiling Market Regional And Country Analysis

• 7.1. Global Cancer Profiling Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer Profiling Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Profiling Market

• 8.1. Asia-Pacific Cancer Profiling Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Profiling Market

• 9.1. China Cancer Profiling Market Overview
• 9.2. China Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Profiling Market

• 10.1. India Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Profiling Market

• 11.1. Japan Cancer Profiling Market Overview
• 11.2. Japan Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Profiling Market

• 12.1. Australia Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Profiling Market

• 13.1. Indonesia Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Profiling Market

• 14.1. South Korea Cancer Profiling Market Overview
• 14.2. South Korea Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Profiling Market

• 15.1. Western Europe Cancer Profiling Market Overview
• 15.2. Western Europe Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Profiling Market

• 16.1. UK Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Profiling Market

• 17.1. Germany Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Profiling Market

• 18.1. France Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Profiling Market

• 19.1. Italy Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Profiling Market

• 20.1. Spain Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Profiling Market

• 21.1. Eastern Europe Cancer Profiling Market Overview
• 21.2. Eastern Europe Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Profiling Market

• 22.1. Russia Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Profiling Market

• 23.1. North America Cancer Profiling Market Overview
• 23.2. North America Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Profiling Market

• 24.1. USA Cancer Profiling Market Overview
• 24.2. USA Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Profiling Market

• 25.1. Canada Cancer Profiling Market Overview
• 25.2. Canada Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Profiling Market

• 26.1. South America Cancer Profiling Market Overview
• 26.2. South America Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Profiling Market

• 27.1. Brazil Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Profiling Market

• 28.1. Middle East Cancer Profiling Market Overview
• 28.2. Middle East Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Profiling Market

• 29.1. Africa Cancer Profiling Market Overview
• 29.2. Africa Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Profiling Market Competitive Landscape And Company Profiles

• 30.1. Cancer Profiling Market Competitive Landscape
• 30.2. Cancer Profiling Market Company Profiles
  • 30.2.1. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. NeoGenomics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sysmex Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. HTG Molecular Diagnostics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Profiling Market Other Major And Innovative Companies

• 31.1. Caris Life Sciences
• 31.2. NanoString Technologies Inc.
• 31.3. Guardant Health Inc.
• 31.4. Foundation Medicine Inc.
• 31.5. Roche Diagnostics Corporation
• 31.6. F. Hoffmann-La Roche Ltd.
• 31.7. Thermo Fisher Scientific Inc.
• 31.8. Genscript Biotech Corporation
• 31.9. Tempus Labs Inc.
• 31.10. Hologic Inc.
• 31.11. Predictive Oncology Inc.
• 31.12. Abbott Laboratories
• 31.13. Agilent Technologies Inc.
• 31.14. PerkinElmer Inc.
• 31.15. Siemens Healthineers

32. Global Cancer Profiling Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Profiling Market

34. Recent Developments In The Cancer Profiling Market

35. Cancer Profiling Market High Potential Countries, Segments and Strategies

• 35.1 Cancer Profiling Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer Profiling Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer Profiling Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer